| ²é¿´: 1754 | »Ø¸´: 8 | ||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||||
³ÕÃÎäìÏæÄ¾³æ (ÖøÃûдÊÖ)
|
[½»Á÷]
ºóÁ¢ÆÕÍ×ʱ´ú£º½µÖ¬Ò©ÎïµÄÏÂÒ»Ôö³¤µãÔÚÄÄÀ ÒÑÓÐ8È˲ÎÓë
|
|||
|
¸ù¾ÝFiercePharmaµÄÊý¾Ý£¨www.fiercepharma.com/special-reports/top-10-cardio-drugs-2012£©£¬ÓÉÓÚÊÜרÀûÐüѵÄÓ°Ï죬2012ÄêÐÄѪ¹ÜÒ©ÎïTop10µÄ×ÜÏúÊÛ¶î´Ó2011ÄêµÄ372.71ÒÚÃÀÔª½µÎª286.44ÒÚÃÀÔª¡£ÌرðÊÇ»ÔÈðµÄLiptor£¬2011ÄêÏúÊÛ¶îΪ95.77ÒÚÃÀÔª£¬µ«2012Äê½öÓÐ39.48ÒÚÃÀÔª£¬¶øÄ¿Ç°×ÏúµÄCrestorÒ²½«ÔÚ2016ÄêרÀûµ½ÆÚ£¬Î´À´¼¸ÄêÏ»¬Ç÷ÊÆËÆºõ²»¿ÉÄæ×ª¡£ ¶øDecision Resources×îз¢²¼µÄ±¨¸æÏÔʾ£¬2012-2022Äê¼ä½µÑªÖ¬Ò©ÎïÊг¡ÈÔ½«ÒÔ2%µÄËÙ¶ÈÔö³¤£¬ÖÁ2022Äê´ïµ½310ÒÚÃÀÔª¡£ÐµÄÔö³¤µãÀ´×ÔÁ½ÀàÐÂÒ©£ºCETPÒÖÖÆ¼ÁÓëanti-PCSK9µ¥¿¹£¬¸öÈ˱ȽϿ´ºÃanti-PCSK9µ¥¿¹£¬µ«¶ÔCETPÒÖÖÆ¼ÁûʲôºÃ¸Ð¡£ CETPÈ«³Æµ¨¹Ì´¼õ¥×ªÒƵ°°×£¨cholesterylester transfer protein£©£¬ËüÄÜ´ÙʹVLDL¡¢LDL½«¸ÊÓÍÈýõ¥×ªÒƸøHDL£¬¶ø½«HDLµÄµ¨¹Ì´¼õ¥×ªÒƸøVLDL¡¢LDL£¬Æä½á¹ûÊÇHDL-CϽµ¡¢VLDL-C¡¢LDL-CÉÏÉý¡£ ×îÔçµÄCETPÒÖÖÆ¼ÁÊÇ»ÔÈðµÄtorcetrapib (CP-529414)£¬2006ÄêÒòΪexcessive all-cause mortalityÐû¸æIIIÆÚÁÙ´²Ê§°Ü£¬ËðʧµÄÑз¢·ÑÓÃÔÚ8ÒÚÃÀÔªÒÔÉÏ¡£ÁíÒ»¸ö²»ºÃµÄÏûÏ¢À´×ÔRoche£¬dalcetrapib (JTT-705)Ò²ÓÚ2012ÄêÐû¸æIIIÆÚÁÙ´²Ê§°Ü£¬ÀíÓÉÊÇȱ·¦meaningful efficacy¡£ ÔÚÑеÄÁ½¸öCETPÒÖÖÆ¼ÁÊÇEli LillyµÄevacetrapib (LY2484595)ºÍMerckµÄanacetrapib (MK-0859)£¬Ä¿Ç°Eli LillyµÄpipelineÖÐÕÒ²»µ½evacetrapib£¬¿ÉÄÜÒѾ·ÅÆúIIIÆÚÁÙ´²ÊÔÑé¡£MerckµÄanacetrapibÕýÔÚ×öIIIÆÚÁÙ´²ÊÔÑ飬µ«Õâ¼Ò¹«Ë¾½ü10ÄêµÄ±íÏÖÔ¶²»Èçǰ£¬È¥ÄêµÄ½µÖ¬Ò©Tredaptive£¨ÑÌËá+laropiprant£©¾ÍÔÚIIIÆÚÁÙ´²Ê§°Ü£¬ÈÃÈËÐÄÓÐÓà¼Â¡£ PCSK9È«³Æproprotein convertase subtilisin/kexin type 9£¬2003Äê·¢ÏÖPCSK9µ°°×£¬2006Äê·¢ÏÖPCSK9ÓëLDL-CµÄÁªÏµ£¬Ëæºó³ÉΪ½µÑªÖ¬µÄÈÈÃŰе㡣PCSK9ͨ¹ýÓëLDLRµÄEGF-A½á¹¹Óò½áºÏ£¬ÓÕµ¼LDLR½µ½â£¬´Ó¶øÏµ÷LDL´úл£¬Ôì³ÉLDL»ý¾Û¶øÒýÆð¸ßѪ֬¡£ ˵ÆðPCSK9¾Í²»µÃ²»ÌáRegeneron Pharma£¬Õâ¼ÒÉúÎï¼¼Êõ¹«Ë¾ÒÔ¿ÆÑÐÎÅÃûÓÚÊÀ£¬Ä¿Ç°Òѳɹ¦ÉÏÊÐEylea£¨°¢°ØÎ÷ÆÕ£¬ÓÃÓÚÖÎÁÆÊªÐÔAMD£©¡¢Arcalyst£¨ÁÐÂåÎ÷ÆÕ£¬ÓÃÓÚÖÎÁÆCryopyrinµ°°×Ïà¹Ø×ÛºÏÕ÷£©¡¢Zaltrap£¨ziv-°¢°ØÎ÷ÆÕ£¬ÓÃÓÚÖÎÁƽáÖ±³¦°©£©£¬±»ÓþΪÏÂÒ»¸öAmgen¡£ Alirocumab (REGN727/SAR236553)ÊÇRegeneronµÄÓÖÒ»Æ·ÅÆÔÚÑÐÒ©ÎÓëSanofiºÏ×÷½øÐÐIIIÆÚÁÙ´²ÊÔÑ飬Ŀǰ¸ÃÒ©µÄÊÐֵΪ21ÒÚÃÀÔª¡£×ßÔÚRegeneronÖ®ºóµÄÊÇAmgenµÄAMG145£¬Ä¿Ç°´¦ÓÚIIIÆÚÁÙ´²£¬Ò²ÊÇAmgenµÄÊ×ÒªÔÚÑÐÒ©Îï¡£MerckÒ²²»¸Ê¼Åį×öÁ˸ö1D05-IgG2 (J Lipid Res. 2011, 52, 78-86.)£¬Éд¦ÓÚÔçÆÚÑз¢½×¶Î¡£ [ Last edited by ³ÕÃÎäìÏæ on 2013-8-24 at 03:18 ] |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
»¯Ñ§Ò©ÎïºÏ³É·Ïß¿ª·¢Ó빤ÒÕ |
» ²ÂÄãϲ»¶
¡¾ÕÐÆ¸¡¿Çå±±£¨¼ÃÄÏ£©ÉúÎï¿Æ¼¼ÕÐÆ¸AIÖÆÒ©Ñз¢¼ÆËãÈ˲Å
ÒѾÓÐ18È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ183È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ2È˻ظ´
342Ò»Ö¾Ô¸´ó¹¤ÖÆÒ©×¨Ë¶£¬±¾¿Æ211£¬Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
100701ҩѧרҵÕе÷¼Á£¬5¸öÃû¶î£¬Ò©Îﻯѧרҵ£¬Ö÷ÒªÊÇÌìȻҩÎﻯѧ·½Ïò¼ÓÒ©Àí
ÒѾÓÐ4È˻ظ´
¡¾2026 ˶ʿµ÷¼Á¡¿ È«¹úÖØµãʵÑéÊÒ Ò©Ñ§ »¯Ñ§ ÉúÎïѧ ÉúÎïÓëÒ½Ò©
ÒѾÓÐ0È˻ظ´
ҩѧ »¯Ñ§ ÉúÎïѧ ÉúÎïÓëÒ½Ò© ºÓÄÏʦ·¶´óѧ¿¹²¡¶¾ÐÔ´«È¾²¡´´ÐÂÒ©ÎïÈ«¹úÖØµãʵÑéÊÒ
ÒѾÓÐ0È˻ظ´
½Î÷ʦ´ó»¯Ñ§¹¤³ÌѧԺµ÷¼Á½ñÍí0µã¿ª·Å£¡ ȱ¶î100¸ö£¬Ëٳ壡
ÒѾÓÐ13È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
´Ó»ÔÈðµÄÁ¢ÆÕÍ×̸²úÆ·µÄÉúÃüÖÜÆÚ
ÒѾÓÐ20È˻ظ´
2011È«Çò°ÙǿҩÆó³ö¯
ÒѾÓÐ45È˻ظ´
mollyzhang
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 13 (СѧÉú)
- ½ð±Ò: 10275.1
- É¢½ð: 350
- ºì»¨: 4
- Ìû×Ó: 2490
- ÔÚÏß: 417.4Сʱ
- ³æºÅ: 53071
- ×¢²á: 2004-09-12
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
5Â¥2013-08-24 17:39:12
fengfeng18602
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
ÎçÒ¹½ÖÍ·µÄÀËÈË
- Ó¦Öú: 9 (Ó×¶ùÔ°)
- ½ð±Ò: 8951.3
- É¢½ð: 1110
- ºì»¨: 14
- ɳ·¢: 17
- Ìû×Ó: 1726
- ÔÚÏß: 497.9Сʱ
- ³æºÅ: 409096
- ×¢²á: 2007-06-21
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É

2Â¥2013-08-24 08:54:42
yanghuping
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 100 (³õÖÐÉú)
- ½ð±Ò: 5132.5
- É¢½ð: 2331
- ºì»¨: 8
- ɳ·¢: 1
- Ìû×Ó: 939
- ÔÚÏß: 1100.6Сʱ
- ³æºÅ: 965040
- ×¢²á: 2010-03-08
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
3Â¥2013-08-24 09:49:21
lingqin2013
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1656.5
- Ìû×Ó: 210
- ÔÚÏß: 33.4Сʱ
- ³æºÅ: 2436940
- ×¢²á: 2013-04-26
- רҵ: Ò©Îï¶¾Àí

4Â¥2013-08-24 13:40:27













»Ø¸´´ËÂ¥

5